Ambalal Sarabhai Enterprises Limited (ASE) has announced a significant achievement for its Telerad division, operating under Systronics India Limited. The division has been honored with the 'Best Regional Distributor — Broadcast - West Award' at the prestigious Broadcast India Show 2025, held in Mumbai in October.

Award Details

About Telerad

Telerad, described as a total solution company, has established itself as a leading system integrator in the broadcast industry. The division is known for providing comprehensive end-to-end solutions across various broadcast segments.

Significance of the Award

This recognition underscores Telerad's position as a leader in the broadcast solutions sector. It highlights the division's commitment to:

• Delivering innovative broadcast solutions
• Providing exceptional services to industries
• Maintaining a strong presence in the western region of India

Company's Official Statement

In an official communication to the BSE Limited, Ms. Disha Punjani, Company Secretary & Compliance Officer of Ambalal Sarabhai Enterprises Limited, stated:

"Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that our Telerad (division of Systronics India Limited), has been honored with the 'Best Regional Distributor — Broadcast - West Award' at the Broadcast India Show 2025 held in Mumbai in October 2025."

This award serves as a testament to Telerad's expertise and its significant contributions to the broadcast industry. It also reinforces Ambalal Sarabhai Enterprises Limited's position in the market, particularly in the technology and solutions sector.

The recognition at such a prominent industry event may potentially boost the company's reputation and could lead to increased business opportunities in the broadcast solutions market.

Ambalal Sarabhai Enterprises Limited (ASE) has reported a remarkable financial performance for the first quarter, with a substantial increase in net profit and the formation of a new Pharma Committee to oversee its pharmaceutical business operations.

Financial Highlights

ASE's consolidated net profit for Q1 soared to Rs. 822.35 lakhs, marking an impressive 2270% increase from Rs. 34.71 lakhs in the same quarter last year. This significant jump in profitability showcases the company's strong operational performance and strategic initiatives.

The company's revenue from operations stood at Rs. 4,033.88 lakhs, compared to Rs. 4,069.66 lakhs in the corresponding quarter of the previous year, indicating a marginal decrease of 0.88%.

Segment-wise Performance

ASE operates in two primary segments:

1. Pharmaceuticals: Generated revenue of Rs. 2,546.42 lakhs
2. Electronics: Contributed Rs. 1,487.46 lakhs to the total revenue

The diversified business model has helped the company maintain a stable revenue stream despite challenging market conditions.

Standalone Performance

On a standalone basis, ASE posted a profit after tax of Rs. 690.85 lakhs, compared to Rs. 46.33 lakhs in the corresponding quarter, representing a substantial growth of 1391%.

Key Financial Metrics

Formation of Pharma Committee

In a strategic move to strengthen its pharmaceutical business, ASE's Board of Directors has constituted a new Pharma Committee. The committee comprises:

1. Mr. Kartikeya V. Sarabhai
2. Mr. Mohal K. Sarabhai
3. Mr. Govindprasad Namdeo

The Pharma Committee's primary responsibilities include:

• Strategic review of pharmaceutical operations
• Compliance oversight
• Monitoring business performance

This initiative demonstrates ASE's commitment to enhancing its focus on the pharmaceutical segment and ensuring robust governance in this critical business area.

Conclusion

Ambalal Sarabhai Enterprises Limited's exceptional Q1 performance, characterized by a significant increase in profitability and strategic organizational changes, positions the company well for future growth. The establishment of the Pharma Committee underscores ASE's commitment to strengthening its pharmaceutical business, which could be a key driver of long-term value creation for shareholders.

Investors and market observers will likely keep a close watch on ASE's future quarters to see if this strong performance trend continues and how the new Pharma Committee influences the company's strategic direction in the pharmaceutical sector.